General
Preferred name
ICATIBANT
Synonyms
Firazyr ()
ICATIBANT ACETATE ()
Icatibant (acetate) ()
HOE 140 (acetate) ()
HOE 140 ()
Icatibanto ()
Icatibant accord ()
HOE-140 ()
P&D ID
PD041052
CAS
130308-48-4
138614-30-9
Tags
available
drug
biased GPCR ligand
Approved by
FDA
PMDA
EMA
First approval
2008
Drug indication
Heart failure
Inflammation
Hereditary angioedema
Drug Status
approved
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Icatibant acetate (HOE-140 acetate) is a potent and specific peptide antagonist of bradykinin B2 receptor with an IC50 and Ki of 1.07 nM and 0.798 nM respectively[1][2][3].
DESCRIPTION
Icatibant Acetate, an antagonist of the bradykinin B2 receptor, is used in the treatment of hereditary angioedema.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
0
Organisms
3
Compound Sets
15
BiasDB
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
LSP-MoA library (Laboratory of Systems Pharmacology)
Natural product-based probes and drugs
NCATS Inxight Approved Drugs
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
48
Molecular Weight
1303.66
Hydrogen Bond Acceptors
17
Hydrogen Bond Donors
18
Rotatable Bonds
30
Ring Count
7
Aromatic Ring Count
2
cLogP
-4.39
TPSA
516.22
Fraction CSP3
0.61
Chiral centers
12.0
Largest ring
6.0
QED
0.02
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
bradykinin B2
Bradykinin Receptor
BDKRB2
Indication
angioedema
MOA
Bradykinin Receptor antagonist
Pathway
GPCR/G protein
Biosynthetic Origin
Peptide (Ribosomal)
Therapeutic Indication
Hereditary Angioedema
Therapeutic Class
Immunomodulatory
Antiinflammatory Agents
Source data
